PRIOR AUTHORIZATION REQUEST

Stelara

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL** PA requests.

1	Will the requested medication be used in combination with a biologic disease-modifying antirheumatic drug (DMARD) or targeted synthetic DMARD? [Note: Examples of biologics include but not limited to adalimumab SC products (Humira, biosimilars), Cimzia, etanercept SC products (Enbrel, biosimilars), infliximab IV products (Remicade, biosimilars), Actemra (IV or SC), Simponi, Simponi Aria (IV or SC), Orencia (IV or SC), rituximab IV products (Rituxan, biosimilars), Kineret, Siliq, Cosentyx, Taltz, Ilumya, Skyrizi, Tremfya, Entyvio. Examples of targeted synthetic DMARD include but not limited to Otezla, Olumiant, Rinvoq, or Xeljanz/XR.] [If yes, no further questions.]	Yes	No
2	What is the requested medication?		

If you have any questions, call:
1-888-258-8250

PRIOR AUTHORIZATION REQUEST

[] Stelara INTRAVENOUS (If checked, go to 22)

[] Stelara SUBCUTANEOUS (If checked, go to 3)

3	Is the patient currently receiving the requested medication? [If no, skip to question 8.]	Yes	No
4	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 8.]	Yes	No
5	Does the patient have a previously approved PA on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]	Yes	No
6	Has the patient been established on therapy for at least 3 months? [If yes, skip to question 35.] [If no, skip to question 9.]	Yes	No
7	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 9.] [If no, no further questions.]	Yes	No

8 What is the indication or diagnosis?

[] Plaque Psoriasis (If checked, go to 10)

[] Psoriatic Arthritis (If checked, go to 16)

[] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, no further questions)

[] Ulcerative Colitis (If checked, no further questions)

[] Ankylosing Spondylitis (If checked, no further questions)

[] Other (If checked, no further questions)

9 What is the indication or diagnosis?

[] Plaque Psoriasis (If checked, go to 10)

[] Psoriatic Arthritis (If checked, go to 16)

[] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, go to 24)

PRIOR AUTHORIZATION REQUEST

	[] Ulcerative Colitis (If checked, go to 29)		
	[] Ankylosing Spondylitis (If checked, no further questions)		
	[] Other (If checked, no further questions)		
10	Is the patient greater than or equal to 6 years of age? [If no, no further questions.]	Yes	No
11	Is the requested medication being prescribed by or in consultation with a dermatologist? [If no, no further questions.]	Yes	No
12	Has the patient tried at least TWO traditional systemic agents for psoriasis for at least 3 months such as methotrexate, cyclosporine, acitretin, or psoralen plus ultraviolet A light (PUVA)? [If yes, skip to question 14.]	Yes	No
13	Has the patient experienced an intolerance to at least TWO traditional systemic agents for psoriasis such as methotrexate, cyclosporine, acitretin, or psoralen plus ultraviolet A light (PUVA)? [If no, no further questions.]	Yes	No
14	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
15	Does the dose of the requested medication exceed the FDA approved label dosing for the indication? [No further questions.]	Yes	No
16	Is the patient greater than or equal to 6 years of age? [If no, no further questions.]	Yes	No
17	Has the patient tried TWO conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months such as methotrexate (oral or injectable), leflunomide, hydroxychloroquine and/or sulfasalazine? [If yes, skip to question 19.]	Yes	No
18	Has the patient experienced an intolerance to at least TWO conventional synthetic disease-modifying antirheumatic drug (DMARD) such as methotrexate (oral or injectable), leflunomide, hydroxychloroquine and/or sulfasalazine? [If no, no further questions.]	Yes	No
19	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF	Yes	No

PRIOR AUTHORIZATION REQUEST

	inhibitors Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]		
20	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
21	Does the dose of the requested medication exceed the FDA approved label dosing for the indication? [No further questions.]	Yes	No
22	Will the requested medication be used as induction therapy? [If no, no further questions.]	Yes	No
23	What is the indication or diagnosis? [] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, go to 24) [] Ulcerative Colitis (If checked, go to 29) [] Plaque Psoriasis (If checked, no further questions) [] Psoriatic Arthritis (If checked, no further questions) [] Other (If checked, no further questions)		
24	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
25	Is the patient currently taking or has tried a systemic corticosteroid? [If yes, skip to question 27.]	Yes	No
26	Is systemic corticosteroid contraindicated for the patient? [If no, no further questions.]	Yes	No
27	Has the patient tried ONE other conventional systemic therapy for Crohn's disease or was intolerant to other conventional systemic therapy? [Note: Examples of other agents for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate.] [If no, no further questions.]	Yes	No
28	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitor an adalimumab product (Hadlima, Yusimry, or adalimumab-adbm)? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 33.]	Yes	No

PRIOR AUTHORIZATION REQUEST

	[If no, no further questions.]		
29	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
30	Has the patient had a trial of ONE systemic agent for ulcerative colitis or was intolerant to systemic agent? [Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone.] [If no, no further questions.]	Yes	No
31	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitor an adalimumab product (Hadlima, Yusimry, or adalimumab-adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
32	Has documentation been provided to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib), following treatment failure with adalimumab? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
33	Does the dose exceed FDA approved label dosing for the indication? [If yes, no further questions.]	Yes	No
34	Is the requested medication being prescribed by or in consultation with a gastroenterologist? [No further questions.]	Yes	No
35	What is the indication or diagnosis? [] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, go to 36) [] Plaque Psoriasis (If checked, go to 37) [] Psoriatic Arthritis (If checked, go to 38) [] Ulcerative Colitis (If checked, go to 39) [] Ankylosing Spondylitis (If checked, no further questions) [] Other (If checked, no further questions)		
36	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of a response to therapy include a decrease in symptoms such	Yes	No

PRIOR AUTHORIZATION REQUEST

	as diarrhea, pain, and/or bleeding; and/or improvement in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count (CBC), and/or fecal calprotectin (fCal). The patient may not have a full response, but there should have been a recent or past response to Stelara.] [No further questions.]		
37	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: The patient may not have a full response, but there should have been a recent or past response to Stelara.] [No further questions.]	Yes	No
38	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of a response to therapy include less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improvements in acute phase reactants (for example, C-reactive protein). The patient may not have a full response, but there should have been a recent or past response to Stelara.] [No further questions.]	Yes	No
39	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of a response to therapy include decreased stool frequency or rectal bleeding.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

authorization as per Plan policy and procedures.